{"id":"W2116236442","doi":"10.1186/bcr3484","title":"Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Sunnybrook Health Science Centre","funders":"American Society of Clinical Oncology; AstraZeneca","keywords":"Medicine; Olaparib; Neutropenia; Tolerability; Internal medicine; Febrile neutropenia; PARP inhibitor; Metastatic breast cancer; Taxane; Oncology; Breast cancer; Regimen; Cohort; Adverse effect; Surgery; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004680478,0.0002823369,0.0007546447,0.0003152021,0.0001317487,0.00002527409,0.0001759416,0.00007912173,0.001847282],"category_scores_gemma":[0.00006236486,0.0001474844,0.0001177931,0.001122614,0.0005397858,0.0002581563,0.00003150386,0.0002397348,0.000002629036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001246494,"about_ca_system_score_gemma":0.001600855,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008433552,"about_ca_topic_score_gemma":0.008981326,"domain_scores_codex":[0.9969284,0.0003119821,0.0006443867,0.0004433843,0.00113739,0.000534483],"domain_scores_gemma":[0.9965805,0.0004627595,0.0003810321,0.0004603993,0.001941308,0.000173933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8393635,0.02355682,0.06043271,0.001068471,0.00122555,0.000007989133,0.003195232,0.000109398,0.001337723,0.0001156352,0.003002135,0.0665848],"study_design_scores_gemma":[0.7648706,0.0270954,0.1811973,0.001713242,0.0002567155,0.00002271012,0.0008077931,0.0005730874,0.02203709,0.0002869247,0.0008001727,0.0003388936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814954,0.000125155,0.00004035088,0.004160877,0.0001569359,0.009588486,0.004376137,0.00001341532,0.00004319186],"genre_scores_gemma":[0.9901115,0.000114267,0.0002288314,0.00006721752,0.0001613218,0.008483266,0.00008153657,0.00005593606,0.000696077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1207646,"threshold_uncertainty_score":0.9990652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08670294013995589,"score_gpt":0.4172623707952946,"score_spread":0.3305594306553387,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}